The evidence to date thus supports a step-wise approach to the management of problematic hypoglycaemia, starting with validated structured education programmes transferring the skills of insulin dose adjustment to the users of the insulin, and progressing through use of technology, either pump or sensor, then SAP therapy with automated suspend features. The gene discussed is INS; the disease is Hypoglycemia.